• Home
  • The Science
  • Press and Media
  • Hearing Loss
  • Contact Us
  • Selected Publications

Otologic Pharmaceutics, Inc. successfully completes Phase I trial to treat Noise Induced Hearing Loss

Dec 1, 2015

Otologic Pharmaceutics, Inc. (OPI), a development-stage biopharmaceutical company committed to developing and commercializing novel pharmacological solutions and approaches to treat hearing disorders, announced the successful completion of single and multi-dose Phase...

Recent Posts

  • TINNITUS TOGETHER
  • Boehringer OKs $100M biobucks deal for hearing loss R&D project
  • Response to OKN-007 and NAC in a Patient with UnilateralHearing Loss and Chronic Tinnitus from VestibularSchwannoma
  • Enhanced sucrose-mediated cryoprotection of siRNA-loaded poly (lactic-co-glycolic acid) nanoparticles
  • 2020 – 2021 Updates from Otologic Pharaceutics

Archives

  • December 2023
  • April 2023
  • March 2023
  • December 2022
  • December 2021
  • January 2021
  • April 2018
  • October 2017
  • December 2015
  • April 2014

© 2021 Otologic Pharmaceutics

A portfolio company of Ascend BioVentures